PT804482E - Citoquinas que se ligam ao receptor hek da superficie celular - Google Patents
Citoquinas que se ligam ao receptor hek da superficie celularInfo
- Publication number
- PT804482E PT804482E PT94925915T PT94925915T PT804482E PT 804482 E PT804482 E PT 804482E PT 94925915 T PT94925915 T PT 94925915T PT 94925915 T PT94925915 T PT 94925915T PT 804482 E PT804482 E PT 804482E
- Authority
- PT
- Portugal
- Prior art keywords
- hek
- polypeptides
- cell surface
- cytokins
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Secondary Cells (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10974593A | 1993-08-20 | 1993-08-20 | |
| US11442693A | 1993-08-30 | 1993-08-30 | |
| US16113293A | 1993-12-03 | 1993-12-03 | |
| US08/240,124 US5516658A (en) | 1993-08-20 | 1994-05-09 | DNA encoding cytokines that bind the cell surface receptor hek |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT804482E true PT804482E (pt) | 2004-06-30 |
Family
ID=27493708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT94925915T PT804482E (pt) | 1993-08-20 | 1994-08-17 | Citoquinas que se ligam ao receptor hek da superficie celular |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US5516658A (pt) |
| EP (1) | EP0804482B1 (pt) |
| JP (2) | JP3699477B2 (pt) |
| KR (1) | KR960704038A (pt) |
| AT (1) | ATE259377T1 (pt) |
| AU (1) | AU680540B2 (pt) |
| CA (1) | CA2169851A1 (pt) |
| DE (1) | DE69433552T2 (pt) |
| DK (1) | DK0804482T3 (pt) |
| ES (1) | ES2216000T3 (pt) |
| FI (1) | FI960743A (pt) |
| NO (1) | NO960652L (pt) |
| NZ (1) | NZ271878A (pt) |
| PT (1) | PT804482E (pt) |
| WO (1) | WO1995006065A1 (pt) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2148484A1 (en) * | 1992-11-13 | 1994-05-26 | Stewart Lyman | Novel cytokine designated elk ligand |
| US5516658A (en) * | 1993-08-20 | 1996-05-14 | Immunex Corporation | DNA encoding cytokines that bind the cell surface receptor hek |
| ATE232901T1 (de) * | 1994-04-04 | 2003-03-15 | Regeneron Pharma | Biologisch aktive ligande der eph familie |
| US6303769B1 (en) | 1994-07-08 | 2001-10-16 | Immunex Corporation | Lerk-5 dna |
| USRE37582E1 (en) | 1994-10-05 | 2002-03-12 | Immunex Corporation | Cytokine designated LERK-6 |
| EP0785716B1 (en) | 1994-10-05 | 2006-11-29 | Immunex Corporation | Cytokine designated lerk-6 |
| US5919905A (en) | 1994-10-05 | 1999-07-06 | Immunex Corporation | Cytokine designated LERK-6 |
| AU3251797A (en) * | 1996-07-05 | 1998-02-02 | Mount Sinai Hospital Corporation | Oligomerized receptors which affect pathways regulated by transmembrane ligands for elk-related receptor tyrosine kinases |
| US6448035B1 (en) | 1997-04-24 | 2002-09-10 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR) |
| US6384203B1 (en) | 1999-05-12 | 2002-05-07 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
| AUPO754997A0 (en) * | 1997-06-25 | 1997-07-17 | Leukaemia Foundation Of Queensland, The | Receptor-ligand system and assay therefor |
| US20030198951A1 (en) * | 1999-12-02 | 2003-10-23 | David Mack | Novel methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators |
| US6593110B2 (en) * | 2000-05-04 | 2003-07-15 | California Institute Of Technology | Checkpoint-activating oligonucleotides |
| US20030092035A1 (en) * | 2000-05-04 | 2003-05-15 | Anderson David J. | Pain signaling molecules |
| EP1421190A2 (en) * | 2001-01-16 | 2004-05-26 | Genset | Metabolic gene polynucleotides and polypeptides and uses thereof |
| WO2002078524A2 (en) * | 2001-03-28 | 2002-10-10 | Zycos Inc. | Translational profiling |
| WO2003094859A2 (en) * | 2002-05-10 | 2003-11-20 | Medimmune, Inc. | Epha2 monoclonal antibodies and methods of use thereof |
| US20050152899A1 (en) * | 2002-05-10 | 2005-07-14 | Kinch Michael S. | EphA2 agonistic monoclonal antibodies and methods of use thereof |
| AU2003276832A1 (en) * | 2002-05-10 | 2004-02-25 | Medimmune, Llc | EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF |
| US8461119B2 (en) * | 2002-09-24 | 2013-06-11 | The Burnham Institute | Agents that modulate Eph receptor activity |
| JP2006524693A (ja) * | 2003-04-11 | 2006-11-02 | メディミューン，インコーポレーテッド | ＥｐｈＡ２および非腫瘍性過増殖性細胞障害 |
| CA2522082A1 (en) * | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution |
| TWI476206B (zh) | 2003-07-18 | 2015-03-11 | Amgen Inc | 對肝細胞生長因子具專一性之結合劑 |
| EP1788088B1 (en) * | 2004-07-27 | 2009-05-27 | Riken | Vector expressing human n-deacetylase/n-sulfotransferase 2 |
| CA2595892A1 (en) * | 2005-01-27 | 2006-08-03 | The Burnham Institute | Ephb receptor-binding peptides |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| US9223751B2 (en) * | 2006-09-22 | 2015-12-29 | Intel Corporation | Performing rounding operations responsive to an instruction |
| WO2008103277A2 (en) | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
| NZ583282A (en) | 2007-08-21 | 2012-09-28 | Amgen Inc | Human c-fms antigen binding proteins |
| TWI655210B (zh) | 2010-12-08 | 2019-04-01 | 艾伯維史坦森特瑞斯有限責任公司 | 新穎調節劑及其使用方法 |
| ES2543569T3 (es) | 2011-03-23 | 2015-08-20 | Amgen Inc. | Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3 |
| WO2013025939A2 (en) | 2011-08-16 | 2013-02-21 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| WO2014036022A1 (en) | 2012-08-29 | 2014-03-06 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| AU2014342610A1 (en) | 2013-11-04 | 2016-06-02 | Abbvie Stemcentrx Llc | Anti-EFNA4 antibody-drug conjugates |
| KR102380150B1 (ko) | 2016-03-08 | 2022-03-29 | 얀센 바이오테크 인코포레이티드 | Gitr 항체, 방법, 및 용도 |
| CN116621833A (zh) | 2016-12-22 | 2023-08-22 | 美国安进公司 | Kras g12c抑制剂及其使用方法 |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| EP4141005B1 (en) | 2017-09-08 | 2024-04-03 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
| EP3788053B1 (en) | 2018-05-04 | 2024-07-10 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| CA3098574A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| MA52564A (fr) | 2018-05-10 | 2021-03-17 | Amgen Inc | Inhibiteurs de kras g12c pour le traitement du cancer |
| EP3802535B1 (en) | 2018-06-01 | 2022-12-14 | Amgen, Inc | Kras g12c inhibitors and methods of using the same |
| MA52780A (fr) | 2018-06-11 | 2021-04-14 | Amgen Inc | Inhibiteurs de kras g12c pour le traitement du cancer |
| WO2020050890A2 (en) | 2018-06-12 | 2020-03-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| KR20210093276A (ko) | 2018-11-16 | 2021-07-27 | 암젠 인크 | Kras g12c 억제제 화합물의 주요 중간체의 개선된 합성 |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| US11053226B2 (en) | 2018-11-19 | 2021-07-06 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| US11236069B2 (en) | 2018-12-20 | 2022-02-01 | Amgen Inc. | KIF18A inhibitors |
| WO2020132649A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| MX2021007157A (es) | 2018-12-20 | 2021-08-16 | Amgen Inc | Heteroarilamidas utiles como inhibidores de kif18a. |
| CA3123042A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| WO2020180770A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
| JP2022522777A (ja) | 2019-03-01 | 2022-04-20 | レボリューション メディシンズ インコーポレイテッド | 二環式ヘテロアリール化合物及びその使用 |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| AU2020280024A1 (en) | 2019-05-21 | 2021-12-09 | Amgen Inc. | Solid state forms |
| AU2020326627A1 (en) | 2019-08-02 | 2022-03-17 | Amgen Inc. | KIF18A inhibitors |
| AU2020324406A1 (en) | 2019-08-02 | 2022-03-17 | Amgen Inc. | KIF18A inhibitors |
| CN114391012A (zh) | 2019-08-02 | 2022-04-22 | 美国安进公司 | 作为kif18a抑制剂的吡啶衍生物 |
| EP4007756A1 (en) | 2019-08-02 | 2022-06-08 | Amgen Inc. | Kif18a inhibitors |
| WO2021055728A1 (en) | 2019-09-18 | 2021-03-25 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
| MX2022004656A (es) | 2019-10-24 | 2022-05-25 | Amgen Inc | Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer. |
| MX2022005053A (es) | 2019-10-28 | 2022-05-18 | Merck Sharp & Dohme Llc | Inhibidores de peque?as moleculas de mutante g12c de kras. |
| CN115551500A (zh) | 2019-10-31 | 2022-12-30 | 大鹏药品工业株式会社 | 4-氨基丁-2-烯酰胺衍生物及其盐 |
| MX2022005357A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| CR20220241A (es) | 2019-11-04 | 2022-08-03 | Revolution Medicines Inc | Inhibidores de ras |
| CA3160142A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| US20210139517A1 (en) | 2019-11-08 | 2021-05-13 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| AR120456A1 (es) | 2019-11-14 | 2022-02-16 | Amgen Inc | Síntesis mejorada del compuesto inhibidor de g12c de kras |
| IL292315A (en) | 2019-11-14 | 2022-06-01 | Amgen Inc | Improved synthesis of a kras g12c inhibitory compound |
| JP2023505100A (ja) | 2019-11-27 | 2023-02-08 | レボリューション メディシンズ インコーポレイテッド | 共有ｒａｓ阻害剤及びその使用 |
| WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| WO2021142026A1 (en) | 2020-01-07 | 2021-07-15 | Revolution Medicines, Inc. | Shp2 inhibitor dosing and methods of treating cancer |
| US20230174518A1 (en) | 2020-04-24 | 2023-06-08 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| US20230181536A1 (en) | 2020-04-24 | 2023-06-15 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c |
| BR112022025550A2 (pt) | 2020-06-18 | 2023-03-07 | Revolution Medicines Inc | Métodos para retardar, prevenir e tratar resistência adquirida aos inibidores de ras |
| KR20230031926A (ko) | 2020-07-15 | 2023-03-07 | 다이호야쿠힌고교 가부시키가이샤 | 종양의 치료에 사용되는 피리미딘 화합물을 포함하는 조합 |
| WO2022060583A1 (en) | 2020-09-03 | 2022-03-24 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| JP2023541916A (ja) | 2020-09-15 | 2023-10-04 | レボリューション メディシンズ インコーポレイテッド | がんの治療における、ｒａｓ阻害剤としてのインドール誘導体 |
| EP4267250A1 (en) | 2020-12-22 | 2023-11-01 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
| EP4334324A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| US20230106174A1 (en) | 2021-05-05 | 2023-04-06 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2022250170A1 (en) | 2021-05-28 | 2022-12-01 | Taiho Pharmaceutical Co., Ltd. | Small molecule inhibitors of kras mutated proteins |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2094134A1 (en) * | 1990-10-16 | 1992-04-17 | Vishva M. Dixit | Cytokine-induced marker for inflammatory response |
| JPH04224527A (ja) * | 1990-12-25 | 1992-08-13 | Daikin Ind Ltd | ペンタフルオロジクロロプロパンの製造方法 |
| US5185438A (en) * | 1991-04-02 | 1993-02-09 | The Trustees Of Princeton University | Nucleic acids encoding hencatoporetic stem cell receptor flk-2 |
| US5674691A (en) * | 1991-06-21 | 1997-10-07 | Amrad Corporation Limited | Method of screening for ligands to a receptor-type tyrosine kinase |
| IL107599A0 (en) * | 1992-11-13 | 1994-02-27 | Amgen Inc | Eck receptor ligands |
| CA2148484A1 (en) * | 1992-11-13 | 1994-05-26 | Stewart Lyman | Novel cytokine designated elk ligand |
| US5516658A (en) * | 1993-08-20 | 1996-05-14 | Immunex Corporation | DNA encoding cytokines that bind the cell surface receptor hek |
-
1994
- 1994-05-09 US US08/240,124 patent/US5516658A/en not_active Expired - Lifetime
- 1994-08-17 KR KR1019960700834A patent/KR960704038A/ko not_active Application Discontinuation
- 1994-08-17 WO PCT/US1994/009282 patent/WO1995006065A1/en active IP Right Grant
- 1994-08-17 CA CA002169851A patent/CA2169851A1/en not_active Abandoned
- 1994-08-17 EP EP94925915A patent/EP0804482B1/en not_active Expired - Lifetime
- 1994-08-17 DE DE69433552T patent/DE69433552T2/de not_active Expired - Fee Related
- 1994-08-17 PT PT94925915T patent/PT804482E/pt unknown
- 1994-08-17 DK DK94925915T patent/DK0804482T3/da active
- 1994-08-17 NZ NZ271878A patent/NZ271878A/en not_active IP Right Cessation
- 1994-08-17 AU AU75675/94A patent/AU680540B2/en not_active Ceased
- 1994-08-17 AT AT94925915T patent/ATE259377T1/de not_active IP Right Cessation
- 1994-08-17 JP JP50765095A patent/JP3699477B2/ja not_active Expired - Fee Related
- 1994-08-17 ES ES94925915T patent/ES2216000T3/es not_active Expired - Lifetime
-
1995
- 1995-05-30 US US08/453,943 patent/US5738844A/en not_active Expired - Fee Related
-
1996
- 1996-02-19 FI FI960743A patent/FI960743A/fi unknown
- 1996-02-19 NO NO960652A patent/NO960652L/no not_active Application Discontinuation
-
1998
- 1998-04-08 US US09/057,121 patent/US5969110A/en not_active Expired - Fee Related
-
1999
- 1999-07-21 US US09/358,734 patent/US6274117B1/en not_active Expired - Fee Related
-
2001
- 2001-07-12 US US09/904,954 patent/US6949366B2/en not_active Expired - Fee Related
-
2004
- 2004-02-26 JP JP2004052118A patent/JP3786944B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP3786944B2 (ja) | 2006-06-21 |
| NO960652D0 (no) | 1996-02-19 |
| DE69433552T2 (de) | 2004-12-16 |
| US5969110A (en) | 1999-10-19 |
| DK0804482T3 (da) | 2004-06-07 |
| US5738844A (en) | 1998-04-14 |
| US6949366B2 (en) | 2005-09-27 |
| AU7567594A (en) | 1995-03-21 |
| EP0804482A1 (en) | 1997-11-05 |
| FI960743A0 (fi) | 1996-02-19 |
| FI960743A (fi) | 1996-02-19 |
| US20020010325A1 (en) | 2002-01-24 |
| ES2216000T3 (es) | 2004-10-16 |
| JPH09502174A (ja) | 1997-03-04 |
| EP0804482B1 (en) | 2004-02-11 |
| NZ271878A (en) | 1997-10-24 |
| WO1995006065A1 (en) | 1995-03-02 |
| EP0804482A4 (en) | 2001-05-16 |
| DE69433552D1 (de) | 2004-03-18 |
| CA2169851A1 (en) | 1995-03-02 |
| JP2004187689A (ja) | 2004-07-08 |
| AU680540B2 (en) | 1997-07-31 |
| KR960704038A (ko) | 1996-08-31 |
| US6274117B1 (en) | 2001-08-14 |
| ATE259377T1 (de) | 2004-02-15 |
| JP3699477B2 (ja) | 2005-09-28 |
| US5516658A (en) | 1996-05-14 |
| NO960652L (no) | 1996-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT804482E (pt) | Citoquinas que se ligam ao receptor hek da superficie celular | |
| DE69334100D1 (de) | Elk ligand, ein cytokin | |
| ATE353906T1 (de) | Cd27 ligand | |
| DE69533923D1 (de) | Cytokinin-designiertes lerk-5 | |
| AU4639396A (en) | Cytokine designated lerk-7 | |
| DE69737978D1 (de) | Als 2f1 bezeichnetes rezeptorprotein | |
| ATE215601T1 (de) | Rezeptoren der steroid/thyroid superfamilie von rezeptoren | |
| DE69535719D1 (de) | Fas-antigenbindender ligand | |
| DE58908693D1 (de) | Mischungen von Dispersionsazofarbstoffen. | |
| DE3881023D1 (de) | Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten. | |
| AU7977087A (en) | The use of alpha-2i selective adrenergic receptor agonists in memory enhancement | |
| ATE72356T1 (de) | Schema zum trennen einer bitzeile von einem leseverstaerker. | |
| AU2103700A (en) | Method for the cellular high-throughput-detection of receptor ligand interactions | |
| WO1999067375A3 (en) | Screening system | |
| WO1997036919A3 (en) | Cytokine designated lerk-8 | |
| DK0938555T3 (da) | Konstruktioner og komplekser af cyclin E | |
| MX9700213A (es) | Citocina novedosa designada como lerk-5. | |
| Hourai | Lung Cancer and Cytology | |
| WO1996040937A3 (en) | Adenosine kinase polynucleotides | |
| Fonseca et al. | Duplex System--Its Problems and Development | |
| Greever | Gibson, Arrell," The Santa Fe and Taos Colonies: Age of the Muses, 1900-1942"(Book Review) | |
| JPS6482188A (en) | Character recognizing system | |
| Taffe | The dynamics of two-party politics in Jamaica; implications for development. | |
| 小村敦子 et al. | Toxicoderma Induced by Lentinus Edodes | |
| NO905610D0 (no) | Undertrykkelse av celleproliferasjon ved hjelp av decorin. |